India

Glenmark

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Glenmark to conduct trials in India for potential COVID-19 drug

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

The trials come after a Chinese official told reporters last month that an active ingredient of the drug had been effective, with no obvious side effects, in helping coronavirus patients recover.

Premas Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Premas Biotech to Develop Vaccine Against COVID-19 Based on Multi-Antigenic Approach

Lead Product(s): Recombinant triple antigen vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

Premas Biotech has adopted a three-pronged approach to develop multi subunit vaccine, using recombinantly expressed antigens Spike, Envelope, and Membrane proteins in multiple formats.

Cadila Healthcare Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Department of Biotechnology approves funding for 3 companies for developing COVID-19 vaccine

Lead Product(s): DNA Vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: The Department of Biotechnology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding April 20, 2020

Details:

Funding to support Cadila Healthcare for advancing its DNA Vaccine candidate against SARS-CoV-2 and to Bharat Biotech for COVID-19 vaccine candidate utilising the inactivated rabies vector platform.

Zydus Cadila

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b

Lead Product(s): Interferon alpha-2b

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2020

Details:

Interferon alpha can potentially emerge as one of the treatment options for COVID 19; In vitro and in vivo studies suggest positive effects on COVID-19 Patients.

Seagull Biosolutions

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Pune Firm First in India to Get Govt Funding for COVID-19 Vaccine

Lead Product(s): Active virosome vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: The Union science and technology ministry of India

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding April 12, 2020

Details:

The Union science and technology ministry will fund Seagull Biosolutions to develop a vaccine for Covid-19 which is expected to enter phase-1 trial in 18-20 months.

Vopec Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 26, 2020

Details:

Vopec Pharmaceuticals has received the NOC and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19.

Premas Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

Lead Product(s): Coronvirus vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Akers Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 24, 2020

Details:

Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform and partner with Premas to seek FDA approval.

Zydus Cadila

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Zydus Cadila looks to expedite Covid-19 vaccine development

Lead Product(s): DNA vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 17, 2020

Details:

Adopting a two-pronged approach, a DNA based vaccine and a live attenuated recombinant measles virus vectored vaccine to combat the virus.

Serum Institute of India

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Codagenix partners Serum Institute of India on Covid-19 vaccine

Lead Product(s): Live-attenuated vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Codagenix

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 14, 2020

Details:

Codagenix has designed multiple nCoV vaccine candidate genomes using its proprietary deoptimization technology. The vaccine viruses will then be grown and tested in vivo.

Cipla

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Cipla ready with repurposed HIV drug to combat coronavirus

Lead Product(s): Lopinavir,Ritonavir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Lopinavir and ritonavir - are the protease inhibitors that are designed to block HIV viral replication and are now being repurposed to deal with coronavirus.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Glenmark

Glenmark to conduct trials in India for potential COVID-19 drug

Premas Biotech

Premas Biotech to Develop Vaccine Against COVID-19 Based on Multi-Antigenic Approach

Cadila Healthcare Ltd

Department of Biotechnology approves funding for 3 companies for developing COVID-19 vaccine

Zydus Cadila

Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b

Seagull Biosolutions

Pune Firm First in India to Get Govt Funding for COVID-19 Vaccine

Vopec Pharmaceuticals

Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19

Premas Biotech

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

Zydus Cadila

Zydus Cadila looks to expedite Covid-19 vaccine development

Serum Institute of India

Codagenix partners Serum Institute of India on Covid-19 vaccine

Cipla

Cipla ready with repurposed HIV drug to combat coronavirus